Also found in: Medical.
FAST-1Fork-Head Activin Signal Transducer-1
References in periodicals archive ?
Efficacy data for FAST-2 meets primary endpoint, FAST-1 and FAST-2 combined analysis demonstrates a reduction in time to onset of symptom relief
Nasdaq:KOSP) announced today preliminary results from two pivotal Jerini AG (FSE: JI4) Phase III Icatibant clinical trials, FAST-1 and FAST-2 (For Angioedema Subcutaneous Treatment), for the subcutaneous treatment of hereditary angioedema (HAE), a debilitating and potentially life-threatening genetic disease.
5 hours in FAST-1 as compared to a median time of 4.